Certified Advisory Corp’s Regeneron Pharmaceuticals REGN Stock Holding History

Certified Advisory Corp’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-10	Closed	-$3K	–	805
2018 Q2	$3K	Hold	10	–	–	﹤0.01%	679
2018 Q1	$3K	Hold	10	–	–	﹤0.01%	651
2017 Q4	$3K	Buy	+10	New	+$4.05K	﹤0.01%	617

Other funds holding REGN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Certified Advisory Corp's REGN Position: Q3 2018 in Review

Certified Advisory Corp sold out of Regeneron Pharmaceuticals (REGN) in Q3 2018, closing a stake of 10 shares — an estimated $3K sold.

Certified Advisory Corp first reported a position in REGN in Q4 2017 and held it in 3 quarters. The position peaked at $3K in Q2 2018. 644 funds tracked by Wall St. Rank hold REGN as of Q3 2018.

Certified Advisory Corp reported no remaining Regeneron Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Certified Advisory Corp sold 10 Regeneron Pharmaceuticals shares in Q3 2018, an estimated $3K.
Certified Advisory Corp first reported a position in Regeneron Pharmaceuticals in Q4 2017 and held it in 3 quarters.
Certified Advisory Corp's Regeneron Pharmaceuticals position peaked at $3K in Q2 2018.
644 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2018.

Based on Certified Advisory Corp's 13F filing for Q3 2018, filed 13 Nov 2018.